Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belinostat added to chemotherapy for potentially resectable locally advanced thymic epithelial tumors
2017-002561-21Phase 3Active
- Sponsor
- IFCT
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of belinostat in thymoma, thymic carcinoma (TC) and thymic malignancies (TET) (2 arms), sponsored by IFCT. Primary endpoint: R0 complete resection rate by blinded central pathology review. Started Feb 2018; status: active.
02
Drugs
belinostat
03
Conditions
thymomathymic carcinoma (TC)thymic malignancies (TET)
Beyond the preview
Go deeper on 2017-002561-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002561-21.